The medtech company has been working to restore manufacturing, ordering and shipping operations since it was hit by a cyberattack on March 11.
Stryker restores most manufacturing after cyberattack Read More »
The medtech company has been working to restore manufacturing, ordering and shipping operations since it was hit by a cyberattack on March 11.
Stryker restores most manufacturing after cyberattack Read More »
Federal regulators accused the health system of using its market power to force insurers into “all-or-nothing” contracts. The Justice Department filed a similar lawsuit against OhioHealth last month.
Justice Department sues NewYork-Presbyterian in second hospital antitrust case this year Read More »
Watch this critical discussion on how regulators and biotech companies can bridge the expectation gap during the regulatory review process to ensure novel therapies reach patients in a timely manner—because patients don’t have time to wait.
Webinar: Aligning With the FDA on a Regulatory Pathway To Avoid Decision Day Surprises Read More »
Robert Malone claimed that Andrew Nixon, spokesperson for the Department of Health and Human Services, “trashed” him with the media, adding that he resigned because “I do not like drama.”
After Speaking out of Turn, Malone Steps Down From Vaccine Committee Read More »
Source No se puede negar que el mundo digital está cambiando más rápido que nunca. Dicho esto, la forma en que las personas buscan en línea también está cambiando. Hoy en día, muchos usuarios confían en las herramientas impu …
Agencias Que Ofrecen Servicios de SEO Generativos Impulsados por IA en España Read More »
At the AD/PD annual meeting, Eisai presented real-world data suggesting Leqembi’s long-term safety and efficacy in people homozygous for APOE4, who were identified in trials as being at higher risk of brain bleeds while on the treatment. Alzheon, meanwhile, added further detail to trial results of its candidate in patients with the same genetic profile.
Eisai, Alzheon Drill Down on Promising Results in High-Risk Alzheimer’s Subset Read More »
The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat food allergies in children and adults.
Novartis Keeps Deals Coming With $2B Excellergy Takeover Read More »
While the accelerated approval unlocks only a small market opportunity for Rocket Pharmaceuticals, it will give the biotech a chance to prepare for future product launches, according to analysts at Jefferies.
Rocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future Products Read More »
En la historia de la ciencia, hay nombres que resuenan por un solo descubrimiento fortuito. Otros, como el de Donald J. Cram (1919–2001), se inscriben en el panteón de los grandes por haber enseñado al ser humano a “pensar en tres dimensiones”. Premio Nobel de …
Donald J. Cram: El arquitecto de lo invisible que rediseñó la química moderna Read More »
